A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes [III. fazisu, multicentrikus, randomizalt, kettos-vak, aktiv kontrollos, 24 hetes vizsgalat a metforminnal kombinalt, szajon at alkalmazott napi 50 mg TAK-875 hatasossaganak es biztonsagossaganak ertekelesere 100 mg szitagliptinnel osszehasonlítva II. tipusu diabeteszben szenvedo betegek eseteben]

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes [III. fazisu, multicentrikus, randomizalt, kettos-vak, aktiv kontrollos, 24 hetes vizsgalat a metforminnal kombinalt, szajon at alkalmazott napi 50 mg TAK-875 hatasossaganak es biztonsagossaganak ertekelesere 100 mg szitagliptinnel osszehasonlítva II. tipusu diabeteszben szenvedo betegek eseteben]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Fasiglifam (Primary) ; Metformin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda; Takeda Global Research and Development Center
  • Most Recent Events

    • 27 Dec 2013 Status changed from recruiting to discontinued, as reported by a Takeda media release.
    • 10 Aug 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-000542-19).
    • 31 Jul 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top